Improving kidney cancer treatment using a new vascular therapy
Official title: Vascular image-guided optimization of response (VIGOR) to therapy in kidney cancer
Funded at Ut Southwestern Medical Center · NIH-10871855 · Data updated 2026-11-12
This study is looking at a new treatment for kidney cancer that targets the unusual blood vessels in tumors to help shrink them, and it aims to see how well this treatment works when used with other existing therapies, giving patients a potential new option to improve their care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | July 1, 2020 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $462,812 |
| NIH project number | 5R01CA244579-05 |
| Project ID | NIH-10871855 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with renal cell carcinoma who are seeking advanced treatment options.
✕Less likely to help
Patients with kidney cancer who are not eligible for additional therapies or those with early-stage disease may not benefit from this research.
What this research studies
This research focuses on enhancing kidney cancer treatment by developing a novel vascular disrupting agent (VDA) that targets the abnormal blood vessels in tumors. The approach aims to disrupt the tumor's blood supply, leading to tumor cell death and improved outcomes when combined with existing therapies. Patients may benefit from a new treatment option that could work alongside current medications to better manage their condition. The study will involve testing the effectiveness of this agent in combination with other therapies to determine the best treatment strategy.
Why it matters
Potential benefit: If successful, this research could provide kidney cancer patients with a more effective treatment option that enhances the efficacy of existing therapies.
How similar studies have gone: Previous research has shown promise in using vascular disrupting agents in cancer treatment, indicating potential for success with this novel approach.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Liu, Li — Ut Southwestern Medical Center
- Study coordinator: Liu, Li
Related research
Other NIH-funded projects on the same topics.
-
Maximizing anti-tumor immune responses in kidney cancer
A cutting-edge program at UT Southwestern aims to speed up better immunotherapy options for kidney cancer by studying how to activate both innate and adaptive immune responses.
-
Kidney Cancer Career Enhancement Program (CEP) at DF/HCC
A career-boosting program supports junior investigators studying kidney cancer to help them advance in basic, translational, and clinical work.
-
Kidney Cancer Development Program at DF/HCC
A funded program at Dana-Farber/Brigham and Women’s Kidney Cancer Center supports new ideas from researchers to improve understanding and treatment of kidney cancer.
-
Personalized antigens for kidney cancer therapy
This grant explores identifying and targeting tumor-specific antigens in kidney cancer to develop more effective, personalized immunotherapies.
-
Optimizing Anti-PD1 Therapy for High-Risk and Metastatic Kidney Cancer
A large cancer research grant is testing how best to use anti-PD-1 therapy to help people with high-risk and metastatic kidney cancer live longer and with fewer side effects.
-
Targeting the HIF2 Pathway in Kidney Cancer
A cancer treatment program aims to see if a drug called belzutifan can help people with a specific kind of kidney cancer whose growth is driven by the HIF2 pathway.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.